Inovio Pharmaceuticals, Inc. (INO) compared with its closest peers (EQ, SPRB, HURA, ANIX, GNLX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Equillium, Inc. (EQ) | $145.20M | -4.0 |
| Spruce Biosciences, Inc. (SPRB) | $141.05M | -1.7 |
| TuHURA Biosciences, Inc. (HURA) | $127.13M | -1.2 |
| Anixa Biosciences, Inc. (ANIX) | $126.06M | -12.1 |
| Genelux Corporation (GNLX) | $122.61M | -5.1 |
| Neonc Technologies Holdings, Inc. (NTHI) | $121.38M | -2.6 |
| Cumberland Pharmaceuticals Inc. (CPIX) | $114.10M | -20.5 |
| Coya Therapeutics, Inc. (COYA) | $114.01M | -4.6 |
| Rafael Holdings, Inc. (RFL) | $109.89M | -1.6 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $103.68M | — |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
INO overview · INO earnings · INO financials · INO KPIs · INO investor relations · INO ownership · INO filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.